Non-Hodgkin's Lymphoma Clinical Trial
Official title:
Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) vs Fludarabine and Rituximab (F-R) for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT number | NCT00577161 |
Other study ID # | PIX303 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | September 2007 |
Est. completion date | July 2012 |
Verified date | October 2020 |
Source | CTI BioPharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and reduced
delayed cardiotoxicity in animal models compared to reference standards. This cytotoxic agent
has structural similarities to mitoxantrone as well as general similarities to anthracyclines
(such as the tricyclic central quinoid chromophore7).
This phase III study will compare the efficacy and safety of the combination BBR 2778,
fludarabine, and rituximab with the combination fludarabine and rituximab in patients with
relapsed or refractory indolent non-Hodgkin's lymphoma.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 2012 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria 1. Histologically confirmed relapsed or refractory indolent non-Hodgkin's lymphoma (NHL) 2. Any stage (Ann Arbor staging, Appendix 15.7), with or without B symptoms 3. CD 20+ lymphoma (confirmed by immunochemistry) 4. Measurable disease. 5. Atleast 1 prior therapy. 6. Age = 18 years 7. Life expectancy of at least 3 months 8. ECOG performance status (PS) of 0 or 1 9. Adequate cardiac function defined as LVEF = 50% by MUGA scan 10. Adequate renal function 11. Adequate hepatic function 12. Adequate bone marrow function 13. Recovery from all acute toxicities from prior therapies (except alopecia and grade 1 peripheral neuropathy). Exclusion Criteria 1. Prior treatment with a cumulative dose of doxorubicin equivalent exceeding 450 mg/m2 2. Radiotherapy, chemotherapy or other therapies for NHL within 4 weeks of treatment start 3. Systemic corticosteroids to treat NHL within 5 days prior to first dose of study treatment. 4. Radioimmunotherapy (RIT) within 3 months of treatment start 5. Known hypersensitivity to the excipients or the study drugs that the patient will receive 6. Known Type I hypersensitivity or anaphylactic reactions to murine proteins or to any component of rituximab 7. Major thoracic and/or abdominal surgery in the preceding 4 weeks, from which the patient has not fully recovered (patients who have had minor surgery and one week's recovery period may be enrolled) 8. HIV-related lymphoma 9. Active CNS involvement 10. Clinically significant cardiovascular abnormalities 11. Serious (NCI CTCAE grade 3-4) intercurrent infection at randomization, infection requiring oral antibiotics, or deep-seated or systemic mycotic infections. 12. Investigational study drug within 30 days before randomization. Patient must have recovered from all side effects of other investigational therapy. 13. Clinical symptoms suggesting unresolved HIV, HBV or HCV infection. . 14. History of another malignancy except: curatively treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in remission, or any other cancer from which the patient has been disease-free for 5 years 15. Pregnant or lactating women 16. Potentially fertile men and women and their sexual partners not willing to use adequate contraception as defined by the Investigator during the study and for 6 months after the last day of study drug administration |
Country | Name | City | State |
---|---|---|---|
United States | Cancer Care Center | Albany | New York |
United States | Hematology Oncology Consultants | Columbus | Ohio |
United States | Capitol Comprehensive Cancer Care | Jefferson City | Missouri |
United States | Heartland Hematology Oncology Associates | Kansas City | Missouri |
United States | Northwest Alabama Cancer Center | Muscle Shoals | Alabama |
United States | Utah Hematology Oncology, P.C. | Ogden | Utah |
United States | Ventura County Hematology Oncology Specialist | Oxnard | California |
United States | Interlakes Foundation, Inc. | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
CTI BioPharma |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression-free survival | day 64-71 | ||
Secondary | response rate, survival, safety | every 21 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Completed |
NCT04152148 -
A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients
|
Phase 1 | |
Recruiting |
NCT05096234 -
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
|
Phase 2 | |
Recruiting |
NCT05191225 -
Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study
|
Phase 4 | |
Recruiting |
NCT05623982 -
Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03664635 -
MB-CART20.1 Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
Terminated |
NCT01699581 -
Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT01763398 -
Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study
|
N/A | |
Completed |
NCT01205503 -
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
|
Phase 2 | |
Completed |
NCT00969462 -
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma
|
Phase 4 | |
Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
Completed |
NCT00659425 -
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Terminated |
NCT00475332 -
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
|
Phase 2 | |
Completed |
NCT00533728 -
Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00608907 -
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
|
Phase 1 | |
Completed |
NCT00430352 -
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
|
Phase 4 | |
Completed |
NCT00581646 -
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
|
N/A | |
Completed |
NCT00150462 -
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
Phase 1 |